simplSEQ

SEQUENCING.SIMPLIFIED.

A Breakthrough in Sequencing
When sequencing DNA and RNA from a biological sample, the material is "used up" in the process. If there is a need to run further tests, another sample needs to be procured. This can be very difficult when using a biopsy sample, and in any case this requires additional time and resources for specimen collection.

Introducing SimplSeq™
SimplSeq has created an entirely new approach to extracting, purifying, replicating and preparing samples for sequencing.

Due to our proprietary technology (patents pending) we can preserve the original DNA or RNA material!

This breakthrough alone will transform the genomic sequencing world. Now labs will be able to "biobank" DNA and RNA samples for future testing.

Thousands of labs are running millions of samples today that could benefit from this new technology.

In addition to preserving the sequenced material, the SimplSeq processing approach is also **faster**, **cheaper** and **better.**

Our process requires fewer steps than the traditional methods of sample preparation, increasing lab throughput. The reduction in labor time lowers overall costs. Fewer steps also means less opportunity for errors.

By simplifying the process, the need for specialized technical knowledge is eliminated, allowing general lab technicians to run the samples and further reducing costs. This also brings genomic sequencing ability to hospitals and other point of care facilities that until now had to rely on outsourcing their genomic sequencing.

The SimplSeq approach eliminates the need for "targeted capture" - allowing labs to collect more information from each sample.

Our approach to simplified sample preparation delivers tangible benefits:

More data, **faster** results, and **lower** price.



The Opportunity
Here is a chance to get in on one of the fastest-growing market segments in biotech. Our technology runs on all sequencing platforms – we become the "Intel Inside" for genomic sequencing.

We have validated this technology internally, have filed three patent applications, and plan to conduct external validations this summer. Our validation partners are expected to be major genome centers that will ultimately become our first customers and evangelists.

There is a market for our technology. The few industry people we have talked to are very excited to try this out, and believe this to be transformational. We run a very low overhead and our products are expected to deliver high margins.

We are interested in talking with investors, collaborators and others who will help us bring this valuable technology to market.

Contact John Powers at (847) 404-0644 or Jay Goth at (951) 704-6792.